At the same time, the Group aims to increase its earning power and create value through innovation and growth. land, water and energy. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. Published Jan. 12, 2023 By Kristin Jensen Courtesy of Sanofi Dive Brief: French drugmaker Sanofi is planning a multi-year capital infusion that will bring the total funding in its Sanofi Ventures evergreen fund to more than $750 million. Please note that if you do not provide consent, if you withdraw your consent or object to processing, or if you choose not to provide certain Personal Data, we may be unable to provide you some or all of the Site. Sustainability
Sanofi Ventures is the corporate venture capital arm of Sanofi. in the Pipeline, Trends in
Get the latest business insights from Dun & Bradstreet. We provide these links merely for your convenience.
Breakpoint Therapeutics - Evotec Experience with Ph 1-3 immuno-oncology clinical trials preferred. Please note, however, we cannot fully eliminate security risks associated with the storage and transmission of Personal Data. Australia, Canada or Japan or any other jurisdiction, where access to the materials is prohibited or
Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. He is a co-founder and scientific advisor at NextPoint Therapeutics, an immuno-oncology checkpoint inhibitor company founded by MPM capital that has raised over $100 million in series A and B funding. Requests may be made only once a year and are free of charge. Its products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Patients, Beware of Medical
Leaps by Bayer, a unit of Bayer AG, leads impact investments into solutions to some of todays biggest challenges in health and agriculture.
14 new chief medical officers in February If you are located outside of the United States, the transfer of Personal Data is necessary to provide you with the requested information and Site and/or to perform any requested transaction. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Innovations, Redefining
Slavery Act Statement, Position
Deforestation and Forest Degradation, Postion
She completed postgraduate training at Massachusetts General Hospital and at Dana-Farber Cancer Institute in Boston. This Privacy Notice is intended to describe how NextPoint Therapeutics, Inc., (NextPoint) collects, uses, and shares Personal Data that you submit to us and that we collect through our websitehttps://www.nextpointtx.com(the Site). Member State, except that an offer to the public in such Relevant Member State of any securities may
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the . We are thrilled to support NextPoint, an exciting addition to our oncology portfolio, as it works to redefine the treatment landscape of immuno-oncology.. Development, Test CS
NextPoint Therapeutics | VentureRadar prohibited or restricted. About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Results, AGM
designed to prevent, alleviate and treat diseases. on
Interested in finding out more?Please send your resume and cover letter to HR@nextpointtx.com. Existing investors that took part in the financing include MPM Capital Management, Binney Street Capital/Dana-Farber Cancer Institute and NextPoint founder Gordon Freeman, PhD. the
Associate Director, NextPoint Therapeutics, Boston, Massachusetts; Health Data Science Leader, Insight Data Science, San Francisco, California; Self-employed, Medical Writer and Editor at CRL MedWrite; Senior Regulatory Specialist at Enable Injections, Inc., Cincinnati, Ohio; Pharmacogenomics Project Manager, Vanderbilt University Medical Center the Luxembourg Stock Exchange (www.bourse.lu). of
Drs. be communicated, falling within Article 49(2)(a) to (d) of the Order (all such persons together
Due to legal reasons, the following content is only available for specialized journalists. NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. Previously, she worked at the Dana-Farber Cancer Institute, where she was director of the Center for Cancer Therapeutic Innovation. Further, it does
at
Viewing the materials you seek to access may not be lawful in certain
shall form the basis of, or be relied upon in connection with, any offer or commitment
I have a keen interest in retail investing and enjoy long-distance running. 2021 Jul 9;6(61):9792. us, How
NextPoint Therapeutics raises $80 million in Series B financing Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. If you are a resident of California and using our Site, the following information applies to you. Leena is a proven leader in immuno-oncology and a brilliant physician-scientist, and our team will benefit greatly from her academic and drug development expertise as NextPoint moves forward in its next stage of growth, said Detlev Biniszkiewicz, PhD, Chief Executive Officer of NextPoint Therapeutics. Future Leadership Program - Engineers,
If you are not permitted to view materials on this webpage or are in any doubt as to whether you are
2021 Feb;9(2):156-169. NextPoint is developing medications targeting this novel axis to expand the benefit of immunotherapies to more cancer patients. We may update this Privacy Notice from time to time.
Up and down the ladder: The latest comings and goings Further, it does not constitute a
Find company research, competitor information, contact details & financial data for Nextpoint Therapeutics, Inc. of Cambridge, MA. The AP news staff was not involved in its creation.
Nextpoint Secures $4.5M in Non-Dilutive Growth Capital - Nextpoint Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Use the Website to artificially generate traffic or page links to a website or for any other purpose not expressly allowed under these Terms. Find out more: www.sanofiventures.com, Find more information at https://pharma.bayer.com/, Follow us on Facebook: http://www.facebook.com/bayer. Counterfeits, Recognizing
Phone:
Compact, Group
The securities referred to herein will not be registered under the U.S. Securities Act of 1933, as
Angela Poppe Ries, MD, was named chief medical officer of VyncaCare, a home healthcare company for patients living with serious illness. Headquarters, Dominican
NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. Safety, Climate
Do-Not-Track is a public-private initiative that has developed a flag or signal that an Internet user may activate in the users browser software to notify websites that the user does not wish to be tracked by third-parties as defined by the initiative. Vote, Voting
Protection, Health and
By clicking on the I AGREE button, I certify that I am not located in the United States,
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs. & Impact, Benefits
As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Investing in a stronger future - for our shareholders, and
jurisdictions, only certain categories of person may be allowed to view such materials. expression Prospectus Directive includes any relevant implementing measure in each Relevant Member
Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. KIR3DL3 Is an Inhibitory Receptor for HHLA2 that Mediates an Alternative Immunoinhibitory Pathway to PD1. If we become aware that an individual under 13 years has provided us with Personal Data without parental consent, we will take steps to remove the data as permitted by law. Distances, Work
Lauren ArnoldMacDougall Advisors1(617)694-5387larnold@macdougall.bio, Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells. Join to view profile NextPoint Therapeutics, Inc. . Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold
in the United States, Australia, Canada, South Africa or Japan or any other jurisdiction, where
Stories, Annual
Scientists, At
For more information, go to www.bayer.com. transaction not subject to, the registration requirements of the Securities Act. Use the Website for any purpose that is unlawful or prohibited by these Terms. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. 5. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. In other jurisdictions, only certain categories of person may be allowed to view such
and Follow-up Questions, How to
Our use or disclosure of de-identified or anonymized data is not subject to this Privacy Notice. indirectly, in or into the United States by use of the mails or by any means or instrumentality
OriCell Therapeutics-Committed to developing novel immunotherapies Sustainable Development Goals, Position
Most browsers allow you to control cookies, including whether or not to accept them, and how to remove them. for
You are currently on the Bayer global
requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. Our Privacy Notice does not apply to Third-Party Sites. Sterling National Bank is providing $2.5 million in a senior facility, and Bigfoot Capital is providing $2.0m in mezzanine financing. NextPoints outstanding team of scientists who have characterized the HHLA2 pathway along with experienced drug developers in the management team makes for the ideal chemistry to usher these novel immuno-oncology programs into the clinic..
NextPoint (Drug Discovery) Company Profile: Valuation & Investors Fighting Counterfeit Drugs, New Safety
In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Human
As part of the financing, Rakhshita Dhar, Senior Director of Venture Investments Health at Leaps by Bayer, and Paulina Hill, Partner at Sanofi Ventures, will join the NextPoint Board of Directors. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. Science, Our
Consulting, Our
Reports, Bayer AG
This website is intended to provide information to an international audience outside the USA and UK. Find out more: This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Monsanto, How to
Natural Scientists, Global
Sweetwater, TX (79556) Today. not constitute a recommendation by Bayer, or any other party to buy or sell securities issued by
This announcement does not contain or constitute an offer of, or the solicitation of an offer to
Financial
PDF Kurt focuses his practice on meeting the business and legal needs of In Dr. Gandhis next role as Vice President of Immuno-Oncology Development at Eli Lilly, she led the development of novel immuno-oncology agents across cancer types before returning to Dana-Farber in 2020, where she most recently served as the Director of the Center for Cancer Therapeutic Innovation a cross-malignancy novel therapeutics hub. Features
Some cookies and other technologies may serve to track Personal Data previously entered by a web user on our site. NextPoints programs aim to deliver monotherapies for cancer patients without viable treatment options. of, Palestinian
language options. Order 2005 (the Order) or (ii) high net worth companies, and other persons to whom it may lawfully
being referred to as relevant persons). NextPoint Therapeutics Appoints Leena Gandhi, MD, PhD, as Chief Medical Officer, Associate Director/Director, Clinical Operations, You should also understand that our Code of Conduct is based in many instances on principles of applicable law. falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion)
announcements and other documents available in electronic format on this webpage does not constitute
Protection Products & Seeds, Supplier
Committed to developing novel immunotherapies.
Anne Koehler, PhD - Associate Director, Tech OPS Program - LinkedIn One of the candidates, lademirsen, is in a phase 2 trial for the treatment of Alport Syndrome. The Site provides a venue to obtain information about NextPoint, our activities, and products we may offer.
Stock Market | sweetwaterreporter.com | Sweetwater Reporter Our innovative approach integrates foundational science with a defined clinical biomarker to deliver a new class of monotherapies for patients who will not benefit from PD-1/L1 inhibitors. Trends, Rise
To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. The financing will be used to advance NextPoint . Management, Supervisory
For example, you will not use the Website to violate any law, statute or regulation (including, without limitation, those governing export control, consumer protection, unfair competition, anti-discrimination or false advertising). NextPoint Therapeutics, Inc. Street Address 1 Street Address 2; 238 MAIN STREET: City State/Province/Country ZIP/PostalCode Phone Number of Issuer; CAMBRIDGE: MASSACHUSETTS: 02142: 5082041115: 3. Insect Decline, Raising
These factors include those discussed in Bayers public reports which are available on the Bayer website at www.bayer.com.